Literature DB >> 29969746

Prognostic Factors in Clival Chordomas: An Integrated Analysis of 347 Patients.

Yingjie Zou1, Natalie Neale2, James Sun2, Mo Yang3, Harrison Xiao Bai2, Lei Tang4, Zishu Zhang5, Alessandro Landi6, Yinyan Wang7, Raymond Y Huang8, Paul J Zhang9, Xuejun Li10, Bo Xiao3, Li Yang11.   

Abstract

OBJECTIVE: To investigate prognostic factors of clival chordoma using the largest patient set to date.
METHODS: Appropriate studies were identified per search criteria, data satisfying criteria were extracted, and survival analysis was performed to investigate prognostic factors of clival chordoma.
RESULTS: A total of 347 patients from the literature cohort met our inclusion criteria. Of 346 cases in which extent of resection was reported, gross total resection (GTR), subtotal resection, and biopsy were achieved in 118 (34.1%), 205 (59.2%), and 21 (6.1%) cases, respectively. Two (0.6%) subjects did not undergo surgery. Of 185 cases in which surgical approach was reported, 56 (30.3%) underwent an endoscopic transoral approach, 17 (9.2%) microscopic transsphenoidal, 45 (24.3%) endoscopic or microscopic, 45 (24.3%) craniotomy, and 22 (11.9%) other approaches. There was no significant difference in GTR rates of different surgical approaches (P = 0.101). Median follow-up was 46.6 months. The 5- and 10-year rates for progression-free survival (PFS) were 59.2% and 47.9%, respectively. The 5- and 10-year rates for overall survival (OS) were 77.3% and 63.9%, respectively. On multivariate analysis for both PFS and OS, GTR demonstrated significantly improved outcomes when compared with subtotal resection (hazard ratio 0.45, 95% confidence interval 0.22-0.90, P = 0.025 for PFS; hazard ratio 0.20, confidence interval 0.06-0.65, P = 0.008 for OS).
CONCLUSIONS: GTR rates were comparable in different surgical approaches. GTR was a significant predictor of longer PFS and OS in clival chordoma.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Chordoma; Clival; Extent of resection; Surgical approach; Survival

Mesh:

Year:  2018        PMID: 29969746     DOI: 10.1016/j.wneu.2018.06.194

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Microsurgical versus endoscopic trans-sphenoidal approaches for clivus chordoma: a pooled and meta-analysis.

Authors:  Delia Cannizzaro; Maria Pia Tropeano; Davide Milani; Riccardo Spaggiari; Ismail Zaed; Cristina Mancarella; Giovanni Battista Lasio; Maurizio Fornari; Franco Servadei; Andrea Cardia
Journal:  Neurosurg Rev       Date:  2020-05-29       Impact factor: 3.042

2.  Apparent diffusion coefficient as a prognostic factor in clival chordoma.

Authors:  Hyeong-Cheol Oh; Chang-Ki Hong; Kyu-Sung Lee; Yoon Jin Cha; Sung Jun Ahn; Sang Hyun Suh; Hun Ho Park
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

3.  PALB2 as a factor to predict the prognosis of patients with skull base chordoma.

Authors:  Yujia Xiong; Mingxuan Li; Yutao Shen; Tianshun Ma; Jiwei Bai; Yazhuo Zhang
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

4.  Endoscopic endonasal approach for loco-regional recurrent clivus chordomas.

Authors:  Matteo Zoli; Federica Guaraldi; Davide Gori; Riccardo Cavicchi; Giacomo Sollini; Sofia Asioli; Marco Faustini-Fustini; Raffaele Agati; Raffaele Lodi; Caterina Tonon; Ernesto Pasquini; Diego Mazzatenta
Journal:  Brain Spine       Date:  2022-07-30

5.  Clival chordoma in a young male patient: a case report.

Authors:  Aref Zribi; Sonia Ben Nasr; Aya Khemir; Faten Gargouri; Ichrak Ben Abdallah; Issam Msakni; Sana Fendri; Mehdi Balti; Basma Laabidi; Abderrazek Haddaoui
Journal:  Pan Afr Med J       Date:  2020-09-15

6.  Craniovertebral junction chordomas: Case series and strategies to overcome the surgical challenge.

Authors:  Bianca Maria Baldassarre; Giuseppe Di Perna; Irene Portonero; Federica Penner; Fabio Cofano; Raffaele De Marco; Nicola Marengo; Diego Garbossa; Giancarlo Pecorari; Francesco Zenga
Journal:  J Craniovertebr Junction Spine       Date:  2021-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.